Cholangiocarcinoma Market Size, Forecast, Demand, Opportunities, 2034

(MENAFN- Straits Research) Cholangiocarcinoma Market Size & Share Analysis

The global cholangiocarcinoma market size was valued at USD 1.09 billion in 2025 and is projected to grow from USD 1.19 billion in 2026 to USD 2.31 Billion by 2034, registering a CAGR of 8.72% during the forecast period (2026–2034). North America dominated the cholangiocarcinoma market with a share of 46.94% in 2025.

Cholangiocarcinoma treatments are medical therapies and procedures used to manage bile duct cancer through approaches such as chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgery. Cholangiocarcinoma treatments are tracked under HSN Code 3004 (medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses) and SIC Code 2836 (biological products, except diagnostic substances), depending on the specific products included in the market.

The cholangiocarcinoma market demand is driven by the prevalence of bile duct cancer and a focus on early diagnosis and personalized treatment. Healthcare providers are adopting targeted therapies, immunotherapies, and molecular diagnostic testing, contributing to cholangiocarcinoma market growth.

Cholangiocarcinoma Market Key TakeawaysGlobal Market Size & Growth2025 Market Size USD 1.09 Billion2026 Market Size USD 1.19 Billion2034 Projected Market Size USD 2.31 BillionForecast Period 2026-2034Base Year 2025Market CAGR (2026-2034) 8.72%Regional Insights Largest Regional Market (2025) North America North America Market Share (2025) 46.94% Fastest-growing Region Asia Pacific Asia Pacific CAGR (2026-2034) 10.03%Segment Insights By Cancer Type Leading Segment Intrahepatic CCA Market Share in 2025 57.8% By Treatment Type Fastest-growing Segment Targeted therapy CAGR 12.28% (2026-2034) By Biomarker Leading Segment FGFR2 Market Share in 2025 28.3%

Download a Free Sample To learn more about this report.

01

Development of Next-Generation FGFR Inhibitors to Overcome Acquired Resistance

The cholangiocarcinoma market analysis shows that treatment research is increasingly focusing on overcoming resistance to fibroblast growth factor receptor 2 (FGFR2)-targeted therapies. This encourages pharmaceutical companies to investigate next-generation inhibitors and alternative treatment combinations that address resistance mechanisms in FGFR2-altered tumors. Researchers are evaluating alternative FGFR-targeting approaches and combination regimens to address acquired resistance associated with FGFR2 alterations.

02

Adoption of Broad Molecular Profiling Before Treatment Selection

Comprehensive molecular profiling identifies actionable genetic alterations before treatment decisions are made. This transition is encouraging healthcare providers to assess biomarkers such as FGFR2 fusions, IDH1 mutations, and HER2 alterations to determine whether patients may qualify for targeted therapies or biomarker-specific clinical trials. The National Comprehensive Cancer Network recommends molecular profiling for patients with unresectable or metastatic biliary tract cancer to help identify potentially actionable alterations and guide treatment selection.

01

Supply chain disruptions are expected to have a moderate impact on the cholangiocarcinoma market share due to dependence on oncology drugs, chemotherapy agents, targeted therapies, diagnostic reagents, and specialized medical supplies. The market is likely to follow an S-shaped recovery, with gradual restoration of pharmaceutical supplies, diagnostic materials, and treatment delivery operations. Supply chain constraints could reduce market growth by 1.0–1.5 percentage points, lowering the projected CAGR of 8.72% to around 7.22%–7.72%. As supply conditions normalize, the cholangiocarcinoma market growth is expected to stabilize.

01

The cholangiocarcinoma market forecasts investment in targeted oncology therapies, immunotherapy, biomarker research, and clinical development programs for bile duct cancer.

02

Key Investment and Funding Activities in CholangiocarcinomaMarket, 2026

Company	Value (USD)	Details
RenovoRx	USD 10 Million	In March 2026, RenovoRx closed an oversubscribed private placement generating approximately USD 10 million in gross proceeds. The financing supports its targeted oncology drug-delivery platform and clinical development programs.
Cholangiocarcinoma Foundation	USD 750,000	In June 2026, the Cholangiocarcinoma Foundation offered an Innovation Award providing USD 750,000 over three years to support research aimed at transforming cholangiocarcinoma care.

Cholangiocarcinoma Market Dynamics 01

Biomarker-Guided Treatment Selection and First-Line Chemo-Immunotherapy Drive Market

Identification of FGFR2 gene fusions in intrahepatic cholangiocarcinoma creates a need for molecular testing to determine patient eligibility for targeted medicines. Oncologists use these test results to select FGFR inhibitors, such as pemigatinib and futibatinib, for eligible patients whose disease progresses after previous treatment. The use of mutation-specific therapies supports demand for molecular diagnostics and targeted medicines in clinical oncology practice.

Durvalumab alongside gemcitabine and cisplatin for unresectable or metastatic cholangiocarcinoma shapes demand for first-line systemic treatment. The TOPAZ-1 clinical trial demonstrated an overall survival benefit from adding durvalumab to chemotherapy, supporting this combination as a treatment option for advanced biliary tract cancer. As oncologists consider this regimen when selecting initial treatment, the demand for immunotherapy and combination drug treatments reflects the need to manage advanced disease.

01

Limited Eligibility for Mutation-Targeted Therapies and Acquired Resistance to FGFR Inhibitors Restrain Market Expansion

FGFR2 fusions and IDH1 mutations occur only in subsets of patients with cholangiocarcinoma, limiting the number of individuals eligible for mutation-specific treatments. The identification of these alterations also depends on access to molecular testing, which adds diagnostic costs and delays treatment selection. Restricted eligible patient population limits the reach of targeted therapies across the cholangiocarcinoma market.

Acquired resistance to FGFR inhibitors can reduce treatment effectiveness in patients with FGFR2-altered cholangiocarcinoma. Additional molecular changes in tumor cells allow the disease to progress despite an initial treatment response, creating a need for alternative therapies and further clinical evaluation.

01

Development of FGFR2 Inhibitors Targeting Resistance Mutations and Expansion of Liver-Directed Therapies Offers Growth Opportunities

Emergence of acquired resistance to FGFR inhibitors is creating opportunities for pharmaceutical companies to develop next-generation treatments that target resistance-associated mutations in FGFR2-altered cholangiocarcinoma. These therapies help address disease progression after initial treatment and extend treatment options for patients with advanced disease.

Liver-directed therapies, including radioembolization, hepatic arterial infusion chemotherapy, and selected ablation techniques, create opportunities to manage cholangiocarcinoma in patients who are unsuitable for surgical resection. These approaches support localized disease control and complement systemic treatment in carefully selected patients.

Cholangiocarcinoma Market Segmentation AnalysisBy Cancer Type

Intrahepatic CCA led the cancer type category with a share of 57.8% in 2025, supported by the occurrence of tumors within the liver's bile ducts and the need for specialized treatment strategies. Oncology centers continue to prioritize diagnostic evaluation and treatment planning for intrahepatic cholangiocarcinoma, strengthening the segment's position in the market.

Extrahepatic CCA is projected to undergo growth at a CAGR of 8.03% during the forecast period, driven by advancements in diagnostic techniques and increasing demand for effective treatment options for bile duct cancer. The use of targeted therapies and the rising focus on early diagnosis and personalized treatment are expected to support segment growth across specialized oncology centers and cancer care facilities.

Request Customization to receive a tailored report.

By Treatment Type

Chemotherapy led the treatment type segment, accounting for a dominant share of 29.4% in 2025. This dominace is led by its widespread use in treating advanced cholangiocarcinoma and controlling disease progression in patients who are not eligible for surgery.

Targeted therapy is likely to witness a CAGR of 12.28% during the forecast period, fueled by the use of molecular testing to identify actionable genetic alterations in cholangiocarcinoma. Increase in availability of biomarker-specific drugs and the shift toward personalized cancer treatment.

By Biomarker

FGFR2 held a dominant share of 28.3% in 2025 due to the clinical relevance of FGFR2 gene alterations in identifying patients who may benefit from targeted treatment.

NTRK is anticipated to record a growth rate of 13.31% during the forecast period, propelled by advances in molecular diagnostics and the identification of NTRK gene fusions as actionable biomarkers in cholangiocarcinoma.

Speak to an Analyst to discuss market opportunities.

Cholangiocarcinoma Market Regional AnalysisNorth America Cholangiocarcinoma Market

North America's cholangiocarcinoma market accounted for a dominant share of 46.94% in 2025.

U.S. Cholangiocarcinoma Market

U.S. Food and Drug Administration (FDA) approved lirafugratinib for adults with previously treated, unresectable, or metastatic cholangiocarcinoma carrying an FGFR2 gene fusion or rearrangement. In the REFOCUS clinical trial involving 116 patients, the treatment achieved an objective response rate of 46% and a median duration of response of 11.8 months, strengthening the U.S. market for biomarker-directed therapies and precision oncology treatments for bile duct cancer.

Canada Cholangiocarcinoma Market

Canada's clinical research landscape continues to advance targeted treatments for cholangiocarcinoma. Health Canada's Clinical Trials Search Portal updated its record for a Phase 1/2 study of CGT4859, an investigational FGFR2/3 inhibitor for cholangiocarcinoma and other advanced solid tumors with relevant genetic alterations. This research supports the development of precision oncology treatments and strengthens opportunities for targeted therapies.

Unlock Regional Insights to access country-level data, & regional trends.

Asia Pacific Cholangiocarcinoma Market

The Asia Pacific cholangiocarcinoma market will expand to 10.03% CAGR during the forecast period, showcasing the fastest-growing regional market.

Japan Cholangiocarcinoma Market

Japan's clinical trial registry updated a Phase 1 study evaluating nanvuranlat, alone or in combination with durvalumab, in 24 patients with unresectable or recurrent biliary tract cancer, including intrahepatic and extrahepatic cholangiocarcinoma. The study evaluates treatment safety, tolerability, and efficacy, including progression-free survival and objective response rate, supporting the development of new systemic treatment options for advanced bile duct cancer in Japan.

China Cholangiocarcinoma Market

China's National Medical Products Administration (NMPA) granted conditional approval to Yochanra (TransThera Sciences) for adults with advanced, metastatic, or unresectable cholangiocarcinoma carrying an FGFR2 fusion or rearrangement who had previously received systemic therapy and an FGFR inhibitor. The approval addresses treatment resistance in this patient group and strengthens China's market for targeted therapies and precision oncology treatments for bile duct cancer.

India Cholangiocarcinoma Market

A multicenter study published in BMC Cancer analyzed genomic profiles from 220 Indian patients with cholangiocarcinoma across three institutions, identifying TP53 mutations in 35.6% of unclassified cases, KRAS mutations in 19.4%, and IDH1 mutations in 10.2%. These findings highlight the importance of population-specific molecular profiling and support opportunities for biomarker testing, precision oncology, and targeted treatment development in India's cholangiocarcinoma market.

Europe Cholangiocarcinoma Market

Europe's cholangiocarcinoma market is likely to grow at a CAGR of 7.94% during the forecast period.

U.K. Cholangiocarcinoma Market

National Institute for Health and Care Excellence (NICE) recommended zanidatamab for routine NHS use in eligible patients with HER2-positive advanced biliary tract cancers, including cholangiocarcinoma, whose disease progressed after first-line treatment. Clinical trial data showed an average overall survival of 18.1 months with zanidatamab, compared with 6.2 months with FOLFOX chemotherapy, supporting access to targeted oncology treatments and strengthening the UK cholangiocarcinoma market.

Germany Companion Animal Vaccine Market

Germany's veterinary vaccination guidance continued to emphasize risk-based immunization protocols for dogs and cats, with core vaccines recommended against canine distemper, parvovirus, and leptospirosis in dogs, and panleukopenia and feline herpesvirus and calicivirus in cats. The guidance supports demand for combination veterinary vaccines and tailored vaccination schedules, strengthening Germany's companion animal vaccine market

Latin AmericaCholangiocarcinoma Market

The Latin America cholangiocarcinoma market is expected to grow at a CAGR of 8.68% during the forecast period. Brazil focuses on expanding specialized oncology services and clinical research into biliary tract cancers, including studies evaluating targeted therapies and immunotherapy for advanced disease. In Mexico, improvements in cancer diagnosis and access to molecular testing are supporting the identification of treatment-relevant biomarkers, including FGFR2 alterations, enabling greater use of targeted therapies for eligible cholangiocarcinoma patients.

Middle East & Africa Cholangiocarcinoma Market

The Middle East & Africa cholangiocarcinoma market is anticipated to grow at a CAGR of 7.72% during the forecast period. Advances in precision oncology are supporting specialized cancer care, with the UAE's 7th Annual Emirates Oncology Society Conference highlighting personalized medicine, molecular testing, and treatment advances for cholangiocarcinoma. In South Africa, an oncology care study published in August 2026 reported an 18% increase in screening coverage for priority cancers and navigation support for 1,943 patients, reflecting improvements in cancer-service access and continuity of care.

Competitive Landscape

The cholangiocarcinoma market competitive landscape includes established pharmaceutical companies and biotechnology firms that develop targeted therapies, immunotherapies, and chemotherapy treatments for bile duct cancer. Key players such as Incyte, AstraZeneca, Merck, F. Hoffmann-La Roche, and Servier are estimated to account for 30–40% of the global cholangiocarcinoma market share.

Established players compete through treatment efficacy, clinical outcomes, biomarker-based drug development, and combination therapies. Emerging players in colangiocarcinoma market ecosystem focus on therapies for specific genetic alterations, targeted treatment approaches, and options for patients with advanced or treatment-resistant cholangiocarcinoma.

List of Key and Emerging Players in Cholangiocarcinoma Market Incyte Corporation (US) AstraZeneca PLC (UK) Merck & Co., Inc. (US) F. Hoffmann-La Roche Ltd. (Switzerland) Servier (France) Taiho Pharmaceutical Co., Ltd. (Japan) Bristol Myers Squibb Company (US) Bayer AG (Germany) Eisai Co., Ltd. (Japan) BeiGene Ltd. (Switzerland) Ono Pharmaceutical Co., Ltd. (Japan) Daiichi Sankyo Company, Limited (Japan)Key Industry Developments September 2026 Elevar Therapeutics submitted a marketing authorization application to the European Medicines Agency for lirafugratinib, an investigational selective FGFR2 inhibitor. August 2026 HUTCHMED received conditional approval from China's National Medical Products Administration for ATLED (fanregratinib). June 2026 June 2026: GENFIT reported positive Phase 1b results for GNS561 in combination with a MEK inhibitor in heavily pretreated patients with KRAS-mutated cholangiocarcinoma. May 2026 Partner Therapeutics received U.S. FDA approval for Bizengri (zenocutuzumab-zbco).Report ScopeSegmentation By Cancer Type 2

Intrahepatic CCA Extrahepatic CCA

By Treatment Type 6

Chemotherapy Immunotherapy Targeted therapy Radiation Therapy Surgical Treatment Palliative Care

By Biomarker 6

FGFR2 IDH1 BRAF HER2 NTRK RET

Geographies Covered North America 2

U.S. Canada

Europe 8

U.K. Germany France Spain Italy Russia Nordic Benelux

APAC 7

China Korea Japan India Australia Taiwan South East Asia

Middle East and Africa 6

UAE Turkey Saudi Arabia South Africa Egypt Nigeria

LATAM 5

Brazil Mexico Argentina Chile Colombia

Competitive Coverage Incyte Corporation (US) · AstraZeneca PLC (UK) · Merck & Co., Inc. (US) · F. Hoffmann-La Roche Ltd. (Switzerland) · Servier (France) Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs) The cholangiocarcinoma market size is valued at USD 1.19 Billion in 2026 and is projected to reach USD 2.31 Billion by 2034, at a CAGR of 8.72% during the forecast period 2026-2034. North America dominated the market with a share of 46.94% in 2025. The leading brands in this market are Incyte Corporation, AstraZeneca PLC, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Servier, Taiho Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Bayer AG, Eisai Co., Ltd., BeiGene Ltd., Ono Pharmaceutical Co., Ltd., and Daiichi Sankyo Company, Limited. The cholangiocarcinoma market is projected to grow at a CAGR of 8.72% during the forecast period of 2026-2034.

MENAFN13112026004597010906ID1111957174